Insulin Resistance and Metabolic Failure Underlie Alzheimer Disease

Metabolic Syndrome and Neurological Disorders

Volumn , Issue , 2013, Pages 1-30

  de la Monte, Suzanne M ^a   Tong, Ming ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Alzheimer disease (AD); Brain insulin resistance; Insulin resistance; Insulin like growth factor (IGF) resistance; Metabolic dysfunction; Neurodegeneration

Indexed keywords

EID: 84978272402     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118395318.ch1     Document Type: Chapter

References (271)

1. Best, C.H. and Scott, D.A., The preparation of insulin. J Biol Chem 1923; 57: 709-23.
2. Roth, J., Qureshi, S., Whitford, I., Vranic, M., Kahn, C.R., Fantus, I.G., and Dirks, J.H., Insulin's discovery: new insights on its ninetieth birthday. Diabetes Metab Res Rev 2012; 28(4): 293-304.
3. Gilchrist, J.A., Best, C.H., and Banting, F.G., Observations with insulin on department of soldiers' civil re-establishment diabetics. Can Med Assoc J 1923; 13(8): 565-72.
4. Gualandi-Signorini, A.M. and Giorgi, G., Insulin formulations-a review. Eur Rev Med Pharmacol Sci 2001; 5(3): 73-83.
5. Heinemann, L. and Richter, B., Clinical pharmacology of human insulin. Diabetes Care 1993; 16 Suppl 3: 90-100.
6. Dave, N., Hazra, P., Khedkar, A., Manjunath, H.S., Iyer, H., and Suryanarayanan, S., Process and purification for manufacture of a modified insulin intended for oral delivery. J Chromatogr A 2008; 1177(2): 282-6.
7. Zeyda, M. and Stulnig, T.M., Obesity, inflammation, and insulin resistance-a mini-review. Gerontology 2009; 55(4): 379-86.
8. Capeau, J., Insulin resistance and steatosis in humans. Diabetes Metab 2008; 34(6 Pt 2): 649-57.
9. Dai, Z., Wu, F., Yeung, E.W., and Li, Y., IGF-IEc expression, regulation and biological function in different tissues. Growth Horm IGF Res 2010; 20(4): 275-81.
10. Matheny, R.W., Jr., Nindl, B.C., and Adamo, M.L., Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology 2010; 151(3): 865-75.
11. Kuemmerle, J.F., Insulin-like growth factors in the gastrointestinal tract and liver. Endocrinol Metab Clin North Am 2012; 41(2): 409-23, vii.
12. de la Monte, S.M. andWands, J.R., Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimer's Dis 2005; 7(1): 45-61.
13. D'Ercole, A.J. and Ye, P., Expanding the mind: insulin-like growth factor I and brain development. Endocrinology 2008; 149(12): 5958-62.
14. Freude, S., Schilbach, K., and Schubert, M., The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. Curr Alzheimer Res 2009; 6(3): 213-23.
15. Zeger, M., Popken, G., Zhang, J., Xuan, S., Lu, Q.R., Schwab, M.H., Nave, K.A., Rowitch, D., D'Ercole, A.J., and Ye, P., Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination. Glia 2007; 55(4): 400-11.
16. de la Monte, S.M., Longato, L., Tong, M., DeNucci, S., and Wands, J.R., The liver-brain axis of alcoholmediated neurodegeneration: role of toxic lipids. Int J Environ Res Public Health 2009; 6(7): 2055-75.
17. de la Monte, S.M., Longato, L., Tong, M., andWands, J.R., Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and nonalcoholic steatohepatitis. Curr Opin Investig Drugs 2009; 10(10): 1049-60.
18. Gronke, S., Clarke, D.F., Broughton, S., Andrews, T.D., and Partridge, L., Molecular evolution and functional characterization of Drosophila insulin-like peptides. PLoS Genet 2010; 6(2): e1000857.
19. Yi, F., Sun, J., Lim, G.E., Fantus, I.G., Brubaker, P.L., and Jin, T., Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology 2008; 149(5): 2341-51.
20. Beildeck, M.E., Gelmann, E.P., and Byers, S.W., Cross-regulation of signaling pathways: an example of nuclear hormone receptors and the canonical Wnt pathway. Experimental cell research 2010; 316(11): 1763-72.
21. Grilli, M., Ferrari Toninelli, G., Uberti, D., Spano, P., and Memo, M., Alzheimer's disease linking neurodegeneration with neurodevelopment. Funct Neurol 2003; 18(3): 145-8.
22. Koo, E.H. and Kopan, R., Potential role of presenilinregulated signaling pathways in sporadic neurodegeneration. Nat Med 2004; 10 Suppl: S26-33.
23. Patapoutian, A. and Reichardt, L.F., Roles of Wnt proteins in neural development and maintenance. Current opinion in neurobiology 2000; 10(3): 392-9.
24. Galceran, J., Miyashita-Lin, E.M., Devaney, E., Rubenstein, J.L., and Grosschedl, R., Hippocampus development and generation of dentate gyrus granule cells is regulated by LEF1. Development 2000; 127(3): 469-82.
25. Ikeya, M., Lee, S.M., Johnson, J.E., McMahon, A.P., and Takada, S., Wnt signalling required for expansion of neural crest and CNS progenitors. Nature 1997; 389(6654): 966-70.
26. Salinas, P.C., Fletcher, C., Copeland, N.G., Jenkins, N.A., and Nusse, R., Maintenance of Wnt-3 expression in Purkinje cells of the mouse cerebellum depends on interactions with granule cells. Development 1994; 120(5): 1277-86.
27. Rao, T.P. and Kuhl, M., An updated overview on Wnt signaling pathways: a prelude for more. Circulation research 2010; 106(12): 1798-806.
28. Tanneberger, K., Pfister, A.S., Kriz, V., Bryja, V., Schambony, A., and Behrens, J., Structural and functional characterization of the Wnt inhibitor APC membrane recruitment 1 (Amer1). The Journal of biological chemistry 2011; 286(22): 19204-14.
29. Roberts, D.M., Pronobis, M.I., Poulton, J.S., Waldmann, J.D., Stephenson, E.M., Hanna, S., and Peifer, M., Deconstructing the sscatenin destruction complex: mechanistic roles for the tumor suppressor APC in regulating Wnt signaling. Molecular biology of the cell 2011; 22(11): 1845-63.
30. MacDonald, B.T., Tamai, K., and He, X., Wnt/betacatenin signaling: components, mechanisms, and diseases. Developmental cell 2009; 17(1): 9-26.
31. Lawton, M., Tong, M., Gundogan, F., Wands, J.R., and de la Monte, S.M., Aspartyl-(asparaginyl) betahydroxylase, hypoxia-inducible factor-alpha and Notch cross-talk in regulating neuronal motility. Oxidative medicine and cellular longevity 2010; 3(5): 347-56.
32. Shanik, M.H., Xu,Y., Skrha, J., Dankner, R., Zick,Y., and Roth, J., Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes care 2008; 31 Suppl 2: S262-8.
33. Dankner, R., Chetrit, A., Shanik, M.H., Raz, I., and Roth, J., Basal-state hyperinsulinemia in healthy normoglycemic adults is predictive of type 2 diabetes over a 24-year follow-up: a preliminary report. Diabetes care 2009; 32(8): 1464-6.
34. Garcia, R.G., Rincon, M.Y., Arenas, W.D., Silva, S.Y., Reyes, L.M., Ruiz, S.L., Ramirez, F., Camacho, P.A., Luengas, C., Saaibi, J.F., Balestrini, S., Morillo, C., and Lopez-Jaramillo, P., Hyperinsulinemia is a predictor of new cardiovascular events in Colombian patients with a first myocardial infarction. Int J Cardiol 2011; 148(1): 85-90.
35. Kasai, T., Miyauchi, K., Kajimoto, K., Kubota, N., Dohi, T., Kurata, T., Amano, A., and Daida, H., The adverse prognostic significance of the metabolic syndrome with and without hypertension in patients who underwent complete coronary revascularization. J Hypertens 2009; 27(5): 1017-24.
36. Agnoli, C., Berrino, F., Abagnato, C.A., Muti, P., Panico, S., Crosignani, P., and Krogh, V., Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis 2010; 20(1): 41-8.
37. Faulds, M.H. and Dahlman-Wright, K., Metabolic diseases and cancer risk. Curr Opin Oncol 2012; 24(1): 58-61.
38. Colonna, S.V., Douglas Case, L., and Lawrence, J.A., A retrospective review of the metabolic syndrome in women diagnosed with breast cancer and correlation with estrogen receptor. Breast Cancer Res Treat 2012; 131(1): 325-31.
39. de la Monte, S.M., Neusner, A., Chu, J., and Lawton, M., Epidemiological Trends Strongly Suggest Exposures as Etiologic Agents in the Pathogenesis of Sporadic Alzheimer's Disease, Diabetes Mellitus, and Non-Alcoholic Steatohepatitis. J Alzheimer's Dis 2009.
40. Cummings, J.L., Definitions and diagnostic criteria. Third ed. Clinical diagnosis and management of Alzheimer's disease. ed. S.Gauthier 2007, London: Informa UK Limited.
41. Gustaw-Rothenberg, K., Lerner, A., Bonda, D.J., Lee, H.G., Zhu, X., Perry, G., and Smith, M.A., Biomarkers in Alzheimer's disease: past, present and future. Biomark Med 2010; 4(1): 15-26.
42. Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., and Selkoe, D.J., Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal longterm potentiation in vivo. Nature 2002; 416(6880): 535-9.
43. Frolich, L., Blum-Degen, D., Bernstein, H.G., Engelsberger, S., Humrich, J., Laufer, S., Muschner, D., Thalheimer, A., Turk, A., Hoyer, S., Zochling, R., Boissl, K.W., Jellinger, K., and Riederer, P., Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 1998; 105(4-5): 423-38.
44. Hoyer, S., Glucose metabolism and insulin receptor signal transduction in Alzheimer's disease. Eur J Pharmacol 2004; 490(1-3): 115-25.
45. Rivera, E.J., Goldin, A., Fulmer, N., Tavares, R., Wands, J.R., and de la Monte, S.M., Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimer's Dis 2005; 8(3): 247-68.
46. Steen, E., Terry, B.M., Rivera, E.J., Cannon, J.L., Neely, T.R., Tavares, R., Xu, X.J., Wands, J.R., and de la Monte, S.M., Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimer's Dis 2005; 7(1): 63-80.
47. de la Monte, S.M., Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Frontiers in bioscience: a journal and virtual library 2012; E4: 1582-605.
48. de la Monte, S.M., Re, E., Longato, L., and Tong, M., Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease. J Alzheimer's Dis 2012; 30(0): S217-29.
49. Caselli, R.J., Chen, K., Lee,W., Alexander, G.E., and Reiman, E.M., Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Arch Neurol 2008; 65(9): 1231-6.
50. Mosconi, L., Pupi, A., and De Leon, M.J., Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 2008; 1147: 180-95.
51. Langbaum, J.B., Chen, K., Caselli, R.J., Lee, W., Reschke, C., Bandy, D., Alexander, G.E., Burns, C.M., Kaszniak, A.W., Reeder, S.A., Corneveaux, J.J., Allen, A.N., Pruzin, J., Huentelman, M.J., Fleisher, A.S., and Reiman, E.M., Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele. Arch Neurol 2010; 67(4): 462-8.
52. Hoyer, S. and Nitsch, R., Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. J Neural Transm 1989; 75(3): 227-32.
53. Hoyer, S., Nitsch, R., and Oesterreich, K., Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a crosssectional comparison against advanced late-onset and incipient early-onset cases. J Neural Transm Park Dis Dement Sect 1991; 3(1): 1-14.
54. Talbot, K., Wang, H.Y., Kazi, H., Han, L.Y., Bakshi, K.P., Stucky, A., Fuino, R.L., Kawaguchi, K.R., Samoyedny, A.J., Wilson, R.S., Arvanitakis, Z., Schneider, J.A., Wolf, B.A., Bennett, D.A., Trojanowski, J.Q., and Arnold, S.E., Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122(4): 1316-38.
55. Lester-Coll, N., Rivera, E.J., Soscia, S.J., Doiron, K., Wands, J.R., and de la Monte, S.M., Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimer's Dis 2006; 9(1): 13-33.
56. Weinstock, M. and Shoham, S., Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity. J Neural Transm 2004; 111(3): 347-66.
57. Bolzan, A.D. and Bianchi, M.S., Genotoxicity of streptozotocin. Mutat Res 2002; 512(2-3): 121-34.
58. Koulmanda, M., Qipo, A., Chebrolu, S., O'Neil, J., Auchincloss, H., and Smith, R.N., The effect of low versus high dose of streptozotocin in cynomolgus monkeys (Macaca fascilularis). Am J Transplant 2003; 3(3): 267-72.
59. de la Monte, S.M., Tong, M., Bowling, N., and Moskal, P., si-RNA inhibition of brain insulin or insulin-like growth factor receptors causes developmental cerebellar abnormalities: relevance to fetal alcohol spectrum disorder. Molecular brain 2011; 4: 13.
60. Salcedo, I., Tweedie, D., Li,Y., and Greig, N.H., Neuroprotective and neurotrophic actions of glucagonlike peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol 2012; 166(5): 1586-99.
61. Piriz, J., Muller, A., Trejo, J.L., and Torres-Aleman, I., IGF-I and the aging mammalian brain. Exp Gerontol 2011; 46(2-3): 96-9.
62. Mattson, M.P., The impact of dietary energy intake on cognitive aging. Front Aging Neurosci 2010; 2: 5.
63. Schubert, M., Gautam, D., Surjo, D., Ueki, K., Baudler, S., Schubert, D., Kondo, T., Alber, J., Galldiks, N.,Kustermann, E., Arndt, S., Jacobs, A.H., Krone, W., Kahn, C.R., and Bruning, J.C., Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 2004; 101(9): 3100-5.
64. Duyckaerts, C., Delatour, B., and Potier, M.C., Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009; 118(1): 5-36.
65. Fraser, P.E., Yu, G., Levesque, L., Nishimura, M., Yang, D.S., Mount, H.T., Westaway, D., and St George-Hyslop, P.H., Presenilin function: connections to Alzheimer's disease and signal transduction. Biochem Soc Symp 2001(67): 89-100.
66. Morales, I., Farias, G., and Maccioni, R.B., Neuroimmunomodulation in the pathogenesis of Alzheimer's disease. Neuroimmunomodulation 2010; 17(3): 202-4.
67. Iqbal, K., Liu, F., Gong, C.X., Alonso Adel, C., and Grundke-Iqbal, I., Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009; 118(1): 53-69.
68. Bhat, R., Xue, Y., Berg, S., Hellberg, S., Ormo, M., Nilsson, Y., Radesater, A.C., Jerning, E., Markgren, P.O., Borgegard, T., Nylof, M., Gimenez-Cassina, A., Hernandez, F., Lucas, J.J., Diaz-Nido, J., andAvila, J., Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003; 278(46): 45937-45.
69. Takashima, A., [Drug development for tauopathy and Alzheimer's disease]. Nihon Shinkei Seishin Yakurigaku Zasshi 2010; 30(4): 177-80.
70. Arnaud, L., Robakis, N.K., and Figueiredo-Pereira, M.E., It may take inflammation, phosphorylation and ubiquitination to 'tangle' in Alzheimer's disease. Neurodegener Dis 2006; 3(6): 313-9.
71. Oddo, S., The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med 2008; 12(2): 363-73.
72. Mandelkow, E.M., Stamer, K., Vogel, R., Thies, E., and Mandelkow, E., Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 2003; 24(8): 1079-85.
73. de la Monte, S.M. and Wands, J.R., Chronic gestational exposure to ethanol impairs insulin-stimulated survival and mitochondrial function in cerebellar neurons. CMLS, Cell Mol Life Sci 2002; 59: 882-893.
74. Bosco, D., Fava, A., Plastino, M., Montalcini, T., and Pujia, A., Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J Cell Mol Med 2011; 15(9): 1807-21.
75. de la Monte, S.M., Chen, G.J., Rivera, E., andWands, J.R., Neuronal thread protein regulation and interaction with microtubule-associated proteins in SHSy5y neuronal cells. Cell Mol Life Sci 2003; 60(12): 2679-91.
76. Doble, B.W. and Woodgett, J.R., GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116(Pt 7): 1175-86.
77. Robakis, N.K., Mechanisms of AD neurodegeneration may be independent of Abeta and its derivatives. Neurobiol Aging 2011; 32(3): 372-9.
78. Wu, L., Rosa-Neto, P., Hsiung, G.Y., Sadovnick, A.D., Masellis, M., Black, S.E., Jia, J., and Gauthier, S., Early-onset familial Alzheimer's disease (EOFAD). Can J Neurol Sci 2012; 39(4): 436-45.
79. Watson, G.S., Peskind, E.R., Asthana, S., Purganan, K.,Wait, C., Chapman, D., Schwartz, M.W., Plymate, S., and Craft, S., Insulin increases CSF Abeta42 levels in normal older adults. Neurology 2003; 60(12): 1899-903.
80. Gasparini, L., Netzer,W.J., Greengard, P., and Xu, H., Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci 2002; 23(6): 288-93.
81. Schuh, A.F., Rieder, C.M., Rizzi, L., Chaves, M., and Roriz-Cruz, M., Mechanisms of brain aging regulation by insulin: implications for neurodegeneration in late-onset Alzheimer's disease. ISRN Neurol 2011; 2011: 306905.
82. Messier, C. and Teutenberg, K., The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease. Neural Plast 2005; 12(4): 311-28.
83. Xie, L., Helmerhorst, E., Taddei, K., Plewright, B., Van Bronswijk, W., and Martins, R., Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 2002; 22(10): RC221.
84. Zheng, W.H., Kar, S., Dore, S., and Quirion, R., Insulin-like growth factor-1 (IGF-1): a neuroprotective trophic factor acting via the Akt kinase pathway. J Neural Transm Suppl 2000(60): 261-72.
85. Tsukamoto, E., Hashimoto, Y., Kanekura, K., Niikura, T., Aiso, S., and Nishimoto, I., Characterization of the toxic mechanism triggered by Alzheimer's amyloid-beta peptides via p75 neurotrophin receptor in neuronal hybrid cells. J Neurosci Res 2003; 73(5): 627-36.
86. Markesbery, W.R. and Carney, J.M., Oxidative alterations in Alzheimer's disease. Brain Pathol 1999; 9(1): 133-46.
87. Reddy, V.P., Zhu, X., Perry, G., and Smith, M.A., Oxidative stress in diabetes and Alzheimer's disease. Journal of Alzheimer's disease: JAD 2009; 16(4): 763-74.
88. Greilberger, J., Fuchs, D., Leblhuber, F., Greilberger, M., Wintersteiger, R., and Tafeit, E., Carbonyl proteins as a clinical marker in Alzheimer's disease and its relation to tryptophan degradation and immune activation. Clinical laboratory 2010; 56(9-10): 441-8.
89. Gu, F., Zhu, M., Shi, J., Hu, Y., and Zhao, Z., Enhanced oxidative stress is an early event during development of Alzheimer-like pathologies in presenilin conditional knock-out mice. Neuroscience letters 2008; 440(1): 44-8.
90. Gella, A. and Durany, N., Oxidative stress in Alzheimer disease. Cell adhesion & migration 2009; 3(1): 88-93.
91. Rahmadi, A., Steiner, N., and Munch, G., Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease. Clinical chemistry and laboratory medicine: CCLM / FESCC 2011; 49(3): 385-91.
92. Krautwald, M. and Munch, G., Advanced glycation end products as biomarkers and gerontotoxins- A basis to explore methylglyoxal-lowering agents for Alzheimer's disease? Experimental gerontology 2010; 45(10): 744-51.
93. Kaplowitz, N., Than, T.A., Shinohara, M., and Ji, C., Endoplasmic reticulum stress and liver injury. Semin Liver Dis 2007; 27(4): 367-77.
94. Malhi, H. and Gores, G.J., Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28(4): 360-9.
95. Sundar-Rajan, S., Srinivasan, V., Balasubramanyam, M., and Tatu, U., Endoplasmic reticulum (ER) stress & diabetes. Indian J Med Res 2007; 125(3): 411-24.
96. de la Monte, S.M. and Tong, M., Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer's disease. J Alzheimer's Dis 2009; 17(4): 817-25.
97. Kaplowitz, N. and Ji, C., Unfolding new mechanisms of alcoholic liver disease in the endoplasmic reticulum. J Gastroenterol Hepatol 2006; 21 Suppl 3: S7-9.
98. Hoyer, S., Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv Exp Med Biol 2004; 541: 135-52.
99. Grunblatt, E., Salkovic-Petrisic, M., Osmanovic, J., Riederer, P., and Hoyer, S., Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 2007; 101(3): 757-70.
100. Chen, G.J., Xu, J., Lahousse, S.A., Caggiano, N.L., and de la Monte, S.M., Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection. J Alzheimer's Dis 2003; 5(3): 209-28.
101. de la Monte, S.M., Tong, M., Lester-Coll, N., Plater, M., Jr., and Wands, J.R., Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimer's Dis 2006; 10(1): 89-109.
102. Gonzalez-Sanchez, J.L. and Serrano-Rios, M., Molecular basis of insulin action. Drug News Perspect 2007; 20(8): 527-31.
103. Etiene, D., Kraft, J., Ganju, N., Gomez-Isla, T., Gemelli, B., Hyman, B.T., Hedley-Whyte, E.T., Wands, J.R., and De La Monte, S.M., Cerebrovascular pathology contributes to the heterogeneity of Alzheimer's disease. J Alzheimer's Dis 1998; 1(2): 119-34.
104. Korf, E.S., White, L.R., Scheltens, P., and Launer, L.J., Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. Diabetes care 2006; 29(10): 2268-74.
105. Kincaid-Smith, P., Hypothesis: obesity and the insulin resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labelled 'hypertensive nephrosclerosis'. J Hypertens 2004; 22(6): 1051-5.
106. Matsumoto, H., Nakao, T., Okada, T., Nagaoka, Y., Iwasawa, H., Tomaru, R., and Wada, T., Insulin resistance contributes to obesity-related proteinuria. Intern Med 2005; 44(6): 548-53.
107. O'Brien, J.T., Role of imaging techniques in the diagnosis of dementia. Br J Radiol 2007; 80 Spec No 2: S71-7.
108. Poljansky, S., Ibach, B., Hirschberger, B., Manner, P., Klunemann, H., Hajak, G., and Marienhagen, J., A visual [18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration. Eur Arch Psychiatry Clin Neurosci 2011; 261(6): 433-46.
109. Teune, L.K., Bartels, A.L., de Jong, B.M.,Willemsen, A.T., Eshuis, S.A., de Vries, J.J., van Oostrom, J.C., and Leenders, K.L., Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord 2010; 25(14): 2395-404.
110. Nijholt, D.A., De Kimpe, L., Elfrink, H.L., Hoozemans, J.J., and Scheper,W., Removing protein aggregates: the role of proteolysis in neurodegeneration. Curr Med Chem 2011; 18(16): 2459-76.
111. Uehara, T., Accumulation of misfolded protein through nitrosative stress linked to neurodegenerative disorders. Antioxid Redox Signal 2007; 9(5): 597-601.
112. Hol, E.M., Fischer, D.F., Ovaa, H., and Scheper, W., Ubiquitin proteasome system as a pharmacological target in neurodegeneration. Expert Rev Neurother 2006; 6(9): 1337-47.
113. Kahle, P.J. and Haass, C., How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep 2004; 5(7): 681-5.
114. Turner, B.J. and Atkin, J.D., ER stress and UPR in familial amyotrophic lateral sclerosis. Curr Mol Med 2006; 6(1): 79-86.
115. Morris, J.K., Seim, N.B., Bomhoff, G.L., Geiger, P.C., and Stanford, J.A., Effects of unilateral nigrostriatal dopamine depletion on peripheral glucose tolerance and insulin signaling in middle aged rats. Neurosci Lett 2011; 504(3): 219-22.
116. Tong, M., Dong, M., and de la Monte, S.M., Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. J Alzheimer's Dis 2009; 16(3): 585-99.
117. Sato, N., Takeda, S., Uchio-Yamada, K., Ueda, H., Fujisawa, T., Rakugi, H., and Morishita, R., Role of insulin signaling in the interaction between Alzheimer disease and diabetes mellitus: a missing link to therapeutic potential. Curr Aging Sci 2011; 4(2): 118-27.
118. Holzenberger, M., Igf-I signaling and effects on longevity. Nestle Nutr Workshop Ser Pediatr Program 2011; 68: 237-45; discussion 246-9.
119. Valentini, S., Cabreiro, F., Ackerman, D., Alam, M.M., Kunze, M.B., Kay, C.W., and Gems, D., Manipulation of in vivo iron levels can alter resistance to oxidative stress without affecting ageing in the nematode C. elegans. Mech Ageing Dev 2012; 133(5): 282-90.
120. Zemva, J., Udelhoven, M., Moll, L., Freude, S., Stohr, O., Bronneke, H.S., Drake, R.B., Krone, W., and Schubert, M., Neuronal overexpression of insulin receptor substrate 2 leads to increased fat mass, insulin resistance, and glucose intolerance during aging. Age (Dordr) 2012.
121. Castilla-Cortazar, I., Garcia-Fernandez, M., Delgado, G., Puche, J.E., Sierra, I., Barhoum, R., and Gonzalez-Baron, S., Hepatoprotection and neuroprotection induced by low doses of IGF-II in aging rats. J Transl Med 2011; 9: 103.
122. Luque, R.M., Lin, Q., Cordoba-Chacon, J., Subbaiah, P.V., Buch, T., Waisman, A., Vankelecom, H., and Kineman, R.D., Metabolic impact of adult-onset, isolated, growth hormone deficiency (AOiGHD) due to destruction of pituitary somatotropes. PLoS One 2011; 6(1): e15767.
123. Srikanth, V., Westcott, B., Forbes, J., Phan, T.G., Beare, R., Venn, A., Pearson, S., Greenaway, T., Parameswaran, V., and Munch, G., Methylglyoxal, cognitive function and cerebral atrophy in older people. J Gerontol A Biol Sci Med Sci 2012.
124. Williamson, R., McNeilly, A., and Sutherland, C., Insulin resistance in the brain: an old-age or newage problem? Biochem Pharmacol 2012; 84(6): 737-45.
125. Oxenkrug, G., Interferon-gamma -inducible inflammation: contribution to aging and aging-associated psychiatric disorders. Aging Dis 2011; 2(6): 474-86.
126. Horrillo, D., Sierra, J., Arribas, C., Garcia-San Frutos, M., Carrascosa, J.M., Lauzurica, N., Fernandez-Agullo, T., and Ros, M., Age-associated development of inflammation inWistar rats: effects of caloric restriction. Arch Physiol Biochem 2011; 117(3): 140-50.
127. Cai, D. and Liu, T., Inflammatory cause of metabolic syndrome via brain stress and NF-kappaB. Aging (Albany NY) 2012; 4(2): 98-115.
128. Birk, T.J., Poliomyelitis and the post-polio syndrome: exercise capacities and adaptation-current research, future directions, and widespread applicability. Med Sci Sports Exerc 1993; 25(4): 466-72.
129. Jubelt, B. and Cashman, N.R., Neurological manifestations of the post-polio syndrome. Crit Rev Neurobiol 1987; 3(3): 199-220.
130. Gordon, T., Hegedus, J., and Tam, S.L., Adaptive and maladaptive motor axonal sprouting in aging and motoneuron disease. Neurol Res 2004; 26(2): 174-85.
131. Dalakas, M.C., Pathogenetic mechanisms of postpolio syndrome: morphological, electrophysiological, virological, and immunological correlations. Ann N Y Acad Sci 1995; 753: 167-85.
132. Chiang, D.J., Pritchard, M.T., and Nagy, L.E., Obesity, diabetes mellitus, and liver fibrosis. American journal of physiology. Gastrointestinal and liver physiology 2011; 300(5): G697-702.
133. Vernon, G., Baranova, A., and Younossi, Z.M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34(3): 274-85.
134. Lyn-Cook, L.E., Jr., Lawton, M., Tong, M., Silbermann, E., Longato, L., Jiao, P., Mark, P.,Wands, J.R., Xu, H., and de la Monte, S.M., Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. J Alzheimer's Dis 2009; 16(4): 715-29.
135. de la Monte, S.M. and Wands, J.R., Alzheimer's disease is type 3 diabetes: evidence reviewed. J Diabetes Sci Tech 2008; 2(6): 1101-113.
136. Kraegen, E.W. and Cooney, G.J., Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol 2008; 19(3): 235-41.
137. Luchsinger, J.A., Reitz, C., Patel, B., Tang, M.X., Manly, J.J., and Mayeux, R., Relation of diabetes to mild cognitive impairment. Arch Neurol 2007; 64(4): 570-5.
138. Craft, S., Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 2007; 4(2): 147-52.
139. Lokken, K.L., Boeka, A.G., Austin, H.M., Gunstad, J., and Harmon, C.M., Evidence of executive dysfunction in extremely obese adolescents: a pilot study. Surgery for obesity and related diseases: official journal of the American Society for Bariatric Surgery 2009; 5(5): 547-52.
140. Gunstad, J., Paul, R.H., Cohen, R.A., Tate, D.F., Spitznagel, M.B., and Gordon, E., Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Comprehensive psychiatry 2007; 48(1): 57-61.
141. Yaffe, K., Metabolic syndrome and cognitive decline. Curr Alzheimer Res 2007; 4(2): 123-6.
142. Winocur, G. and Greenwood, C.E., Studies of the effects of high fat diets on cognitive function in a rat model. Neurobiol Aging 2005; 26 Suppl 1: 46-9.
143. Moroz, N., Tong, M., Longato, L., Xu, H., and de la Monte, S.M., Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimer's Dis 2008; 15(1): 29-44.
144. Baker, L.D., Frank, L.L., Foster-Schubert, K., Green, P.S., Wilkinson, C.W., McTiernan, A., Cholerton, B.A., Plymate, S.R., Fishel, M.A., Watson, G.S., Duncan, G.E., Mehta, P.D., and Craft, S., Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease. J Alzheimer's Dis 2010; 22(2): 569-79.
145. Baker, L.D., Frank, L.L., Foster-Schubert, K., Green, P.S.,Wilkinson, C.W., McTiernan, A., Plymate, S.R., Fishel, M.A.,Watson, G.S., Cholerton, B.A., Duncan, G.E., Mehta, P.D., and Craft, S., Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol 2010; 67(1): 71-9.
146. Bryan, J. and Tiggemann, M., The effect of weightloss dieting on cognitive performance and psychological well-being in overweight women. Appetite 2001; 36(2): 147-56.
147. Gu, Y., Luchsinger, J.A., Stern, Y., and Scarmeas, N., Mediterranean diet, inflammatory and metabolic biomarkers, and risk of Alzheimer's disease. J Alzheimer's Dis 2010; 22(2): 483-92.
148. Pasquier, F., Boulogne, A., Leys, D., and Fontaine, P., Diabetes mellitus and dementia. Diabetes Metab 2006; 32(5 Pt 1): 403-14.
149. Martins, I.J., Hone, E., Foster, J.K., Sunram-Lea, S.I., Gnjec, A., Fuller, S.J., Nolan, D., Gandy, S.E., and Martins, R.N., Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 2006; 11(8): 721-36.
150. Whitmer, R.A., Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep 2007; 7(5): 373-80.
151. Nelson, P.T., Smith, C.D., Abner, E.A., Schmitt, F.A., Scheff, S.W., Davis, G.J., Keller, J.N., Jicha, G.A., Davis, D., Wang-Xia, W., Hartman, A., Katz, D.G., and Markesbery, W.R., Human cerebral neuropathology of type 2 diabetes mellitus. Biochim Biophys Acta 2008.
152. Janson, J., Laedtke, T., Parisi, J.E., O'Brien, P., Petersen, R.C., and Butler, P.C., Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004; 53(2): 474-81.
153. Tong, M., Longato, L., and de la Monte, S.M., Early limited nitrosamine exposures exacerbate high fat diet-mediated type2 diabetes and neurodegeneration. BMC Endocr Disord 2010; 10(1): 4.
154. Whitmer, R.A., Gunderson, E.P., Quesenberry, C.P., Jr., Zhou, J., andYaffe, K., Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res 2007; 4(2): 103-9.
155. Perry,W., Hilsabeck, R.C., and Hassanein, T.I., Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci 2008; 53(2): 307-21.
156. Weiss, J.J. and Gorman, J.M., Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV. Curr HIV/AIDS Rep 2006; 3(4): 176-81.
157. Tong, M., Neusner, A., Longato, L., Lawton, M., Wands, J.R., and de la Monte, S.M., Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. J Alzheimer's Dis 2009.
158. Kao, Y., Youson, J.H., Holmes, J.A., Al-Mahrouki, A., and Sheridan, M.A., Effects of insulin on lipid metabolism of larvae and metamorphosing landlocked sea lamprey, Petromyzon marinus. Gen Comp Endocrinol 1999; 114(3): 405-14.
159. Holland, W.L. and Summers, S.A., Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 2008; 29(4): 381-402.
160. Langeveld, M. and Aerts, J.M., Glycosphingolipids and insulin resistance. Prog Lipid Res 2009; 48(3-4): 196-205.
161. Elwing, J.E., Lustman, P.J., Wang, H.L., and Clouse, R.E., Depression, anxiety, and nonalcoholic steatohepatitis. Psychosom Med 2006; 68(4): 563-9.
162. Felipo, V., Urios, A., Montesinos, E., Molina, I., Garcia-Torres, M.L., Civera, M., Del Olmo, J.A., Ortega, J., Martinez-Valls, J., Serra, M.A., Cassinello, N., Wassel, A., Jorda, E., and Montoliu, C., Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metabolic brain disease 2011.
163. Schmidt, K.S., Gallo, J.L., Ferri, C., Giovannetti, T., Sestito, N., Libon, D.J., and Schmidt, P.S., The neuropsychological profile of alcohol-related dementia suggests cortical and subcortical pathology. Dement Geriatr Cogn Disord 2005; 20(5): 286-91.
164. Kopelman, M.D., Thomson, A.D., Guerrini, I., and Marshall, E.J., The Korsakoff syndrome: clinical aspects, psychology and treatment. Alcohol Alcohol 2009; 44(2): 148-54.
165. de la Monte, S.M., Triangulated mal-signaling in Alzheimer's Disease: Roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. J Alzheimer's Dis 2012; 30: S231-S249.
166. de la Monte, S.M., Tong, M., Lawton, M., and Longato, L., Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment. Mol Neurodegener 2009; 4: 54.
167. de la Monte, S.M., Tong, M., Nguyen, V., Setshedi, M., Longato, L., and Wands, J.R., Ceramidemediated insulin resistance and impairment of cognitive-motor functions. Journal of Alzheimer's disease: JAD 2010; 21(3): 967-84.
168. Tong, M. and de la Monte, S.M., Mechanisms of ceramide-mediated neurodegeneration. J Alzheimer's Dis 2009; 16(4): 705-14.
169. Alessenko, A.V., Bugrova, A.E., and Dudnik, L.B., Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimer's disease. Biochem Soc Trans 2004; 32(Pt 1): 144-6.
170. Adibhatla, R.M. and Hatcher, J.F., Altered lipid metabolism in brain injury and disorders. Subcell Biochem 2008; 49: 241-68.
171. Kassi, E., Pervanidou, P., Kaltsas, G., and Chrousos, G., Metabolic syndrome: definitions and controversies. BMC Med 2011; 9: 48.
172. Tan, Z.S., Beiser, A.S., Fox, C.S., Au, R., Himali, J.J., Debette, S., Decarli, C., Vasan, R.S., Wolf, P.A., and Seshadri, S., Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults: the Framingham Offspring Study. Diabetes Care 2011; 34(8): 1766-70.
173. Debette, S., Beiser, A., Hoffmann, U., Decarli, C., O'Donnell, C.J., Massaro, J.M., Au, R., Himali, J.J., Wolf, P.A., Fox, C.S., and Seshadri, S., Visceral fat is associated with lower brain volume in healthy middle-aged adults. Ann Neurol 2010; 68(2): 136-44.
174. Hassenstab, J.J., Sweat, V., Bruehl, H., and Convit, A., Metabolic syndrome is associated with learning and recall impairment in middle age. Dement Geriatr Cogn Disord 2010; 29(4): 356-62.
175. Frisardi,V., Solfrizzi,V., Capurso, C., Imbimbo, B.P., Vendemiale, G., Seripa, D., Pilotto, A., and Panza, F., Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome? J Alzheimer's Dis 2010; 21(1): 57-63.
176. Yates, K.F., Sweat, V., Yau, P.L., Turchiano, M.M., and Convit, A., Impact of metabolic syndrome on cognition and brain: a selected reviewof the literature. Arterioscler Thromb Vasc Biol 2012; 32(9): 2060-7.
177. Burns, J.M., Honea, R.A., Vidoni, E.D., Hutfles, L.J., Brooks, W.M., and Swerdlow, R.H., Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging. Biochim Biophys Acta 2012; 1822(3): 333-9.
178. Uranga, R.M., Bruce-Keller, A.J., Morrison, C.D., Fernandez-Kim, S.O., Ebenezer, P.J., Zhang, L., Dasuri, K., and Keller, J.N., Intersection between metabolic dysfunction, high fat diet consumption, and brain aging. J Neurochem 2010; 114(2): 344-61.
179. Luchsinger, J.A., Type 2 diabetes, related conditions, in relation and dementia: an opportunity for prevention? J Alzheimer's Dis 2010; 20(3): 723-36.
180. Delgado, J.S., Evolving trends in nonalcoholic fatty liver disease. Eur J Intern Med 2008; 19(2): 75-82.
181. Launer, L.J., Next steps in Alzheimer's disease research: interaction between epidemiology and basic science. Curr Alzheimer Res 2007; 4(2): 141-3.
182. Nugent, C. and Younossi, Z.M., Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2007; 4(8): 432-41.
183. Pradhan, A., Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev 2007; 65(12 Pt 2): S152-6.
184. Rector, R.S., Thyfault, J.P., Wei, Y., and Ibdah, J.A., Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 2008; 14(2): 185-92.
185. Swann, P.F. and Magee, P.N., Nitrosamine-induced carcinogenesis. The alklylation of nucleic acids of the rat by N-methyl-N-nitrosourea, dimethylnitrosamine, dimethyl sulphate and methyl methanesulphonate. Biochem J 1968; 110(1): 39-47.
186. Espey, M.G., Miranda, K.M., Thomas, D.D., Xavier, S., Citrin, D., Vitek, M.P., andWink, D.A., A chemical perspective on the interplay between NO, reactive oxygen species, and reactive nitrogen oxide species. Ann N Y Acad Sci 2002; 962: 195-206.
187. Marchesini, G. and Marzocchi, R., Metabolic syndrome and NASH. Clin Liver Dis 2007; 11(1): 105-17, ix.
188. Nicolls, M.R., The clinical and biological relationship between Type II diabetes mellitus and Alzheimer's disease. Curr Alzheimer Res 2004; 1(1): 47-54.
189. Papandreou, D., Rousso, I., and Mavromichalis, I., Update on non-alcoholic fatty liver disease in children. Clin Nutr 2007; 26(4): 409-15.
190. Pessayre, D., Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2007; 22 Suppl 1: S20-7.
191. Wei, Y., Rector, R.S., Thyfault, J.P., and Ibdah, J.A., Nonalcoholic fatty liver disease and mitochondrial dysfunction.World J Gastroenterol 2008; 14(2): 193-9.
192. Yeh, M.M. and Brunt, E.M., Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007; 128(5): 837-47.
193. Doi, K., [Studies on the mechanism of the diabetogenic activity of streptozotocin and on the ability of compounds to block the diabetogenic activity of streptozotocin (author's transl)]. Nippon Naibunpi Gakkai Zasshi 1975; 51(3): 129-47.
194. Szkudelski, T., The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 2001; 50(6): 537-46.
195. Hoyer, S., Lannert, H., Noldner, M., and Chatterjee, S.S., Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). J Neural Transm 1999; 106(11-12): 1171-88.
196. Iwai, S., Murai, T., Makino, S., Min, W., Morimura, K., Mori, S., Hagihara, A., Seki, S., and Fukushima, S., High sensitivity of fatty liver Shionogi (FLS) mice to diethylnitrosamine hepatocarcinogenesis: comparison to C3H and C57 mice. Cancer Lett 2007; 246(1-2): 115-21.
197. Rossini, A.A., Like, A.A., Chick, W.L., Appel, M.C., and Cahill, G.F., Jr., Studies of streptozotocininduced insulitis and diabetes. Proc Natl Acad Sci U S A 1977; 74(6): 2485-9.
198. Murata, M., Takahashi, A., Saito, I., and Kawanishi, S., Site-specificDNAmethylation and apoptosis: induction by diabetogenic streptozotocin. Biochem Pharmacol 1999; 57(8): 881-7.
199. Nukatsuka, M., Sakurai, H., Yoshimura, Y., Nishida, M., and Kawada, J., Enhancement by streptozotocin of O2-radical generation by the xanthine oxidase system of pancreatic beta-cells. FEBS Lett 1988; 239(2): 295-8.
200. West, I.C., Radicals and oxidative stress in diabetes. Diabet Med 2000; 17(3): 171-80.
201. Labak, M., Foniok, T., Kirk, D., Rushforth, D., Tomanek, B., Jasinski, A., and Grieb, P., Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin: a model of sporadic Alzheimer's disease. Acta Neurochir Suppl 2010; 106: 177-81.
202. Wang, S., Kamat, A., Pergola, P., Swamy, A., Tio, F., and Cusi, K., Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression in vivo. Metabolism 2011; 60(8): 1090-9.
203. Hoyer, S., Muller, D., and Plaschke, K., Desensitization of brain insulin receptor. Effect on glucose/ energy and related metabolism. JNeural Transm Suppl 1994; 44: 259-68.
204. Lannert, H. and Hoyer, S., Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 1998; 112(5): 1199-208.
205. Jin, X., Zeng, L., He, S., Chen, Y., Tian, B., Mai, G., Yang, G., Wei, L., Zhang, Y., Li, H., Wang, L., Qiao, C., Cheng, J., and Lu, Y., Comparison of single high-dose streptozotocin with partial pancreatectomy combined with low-dose streptozotocin for diabetes induction in rhesus monkeys. Exp Biol Med (Maywood) 2010; 235(7): 877-85.
206. Robbiano, L., Mereto, E., Corbu, C., and Brambilla, G., DNA damage induced by seven N-nitroso compounds in primary cultures of human and rat kidney cells. Mutat Res 1996; 368(1): 41-7.
207. Cataldo, J.K., Prochaska, J.J., and Glantz, S.A., Cigarette smoking is a risk factor for Alzheimer's Disease: an analysis controlling for tobacco industry affiliation. J Alzheimer's Dis 2010; 19(2): 465-80.
208. Ertekin-Taner, N., Genetics of Alzheimer disease in the pre-and post-GWAS era. Alzheimers Res Ther 2010; 2(1): 3.
209. Guerreiro, R.J., Gustafson, D.R., and Hardy, J., The genetic architecture of Alzheimer's disease: beyond APP, PSENs and. Neurobiol Aging 2012; 33(3): 437-56.
210. Bekris, L.M., Yu, C.E., Bird, T.D., and Tsuang, D.W., Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 2010; 23(4): 213-27.
211. Maloney, B., Sambamurti, K., Zawia, N., and Lahiri, D.K., Applying epigenetics to Alzheimer's disease via the latent early-life associated regulation (LEARn) model. Curr Alzheimer Res 2012; 9(5): 589-99.
212. Elder, G.A., Gama Sosa, M.A., and De Gasperi, R., Transgenic mouse models of Alzheimer's disease. Mt Sinai J Med 2010; 77(1): 69-81.
213. Bryan, K.J., Lee, H., Perry, G., Smith, M.A., and Casadesus, G., Transgenic Mouse Models of Alzheimer's Disease: Behavioral Testing and Considerations, in Methods of behavior analysis in neuroscience. J.J.Buccafusco, Editor 2009: Boca Raton (FL).
214. Balducci, C. and Forloni, G., APP transgenic mice: their use and limitations. Neuromolecular Med 2011; 13(2): 117-37.
215. Skaper, S.D., Alzheimer's disease and amyloid: culprit or coincidence? Int Rev Neurobiol 2012; 102: 277-316.
216. Brugge, K.L., Nichols, S., Delis, D., Saitoh, T., and Truaner, D., The role of alterations in free radical metabolism in mediating cognitive impairments in Down's syndrome. 1992; 62: 190-8.
217. Marks, A. and Allore, R., S100 protein and Down syndrome. Bioessays 1990; 12(8): 381-3.
218. Nicholson, A.M., Wold, L.A., Walsh, D.M., and Ferreira, A., beta-Amyloid carrying the Dutch mutation has diverse effects on calpain-mediated toxicity in hippocampal neurons. Mol Med 2012; 18: 178-85.
219. Biffi, A., Plourde, A., Shen, Y., Onofrio, R., Smith, E.E., Frosch, M., Prada, C.M., Gusella, J., Greenberg, S.M., and Rosand, J., Screening for familial APP mutations in sporadic cerebral amyloid angiopathy. PLoS One 2010; 5(11): e13949.
220. Bugiani, O., Giaccone, G., Rossi, G., Mangieri, M., Capobianco, R., Morbin, M., Mazzoleni, G., Cupidi, C., Marcon, G., Giovagnoli, A., Bizzi, A., Di Fede, G., Puoti, G., Carella, F., Salmaggi, A., Romorini, A., Patruno, G.M., Magoni, M., Padovani, A., and Tagliavini, F., Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP. Arch Neurol 2010; 67(8): 987-95.
221. Schaeffer, E.L., Figueiro, M., and Gattaz, W.F., Insights into Alzheimer disease pathogenesis from studies in transgenic animal models. Clinics (Sao Paulo) 2011; 66 Suppl 1: 45-54.
222. Wang, X.P. and Ding, H.L., Alzheimer's disease: epidemiology, genetics, and beyond. Neurosci Bull 2008; 24(2): 105-9.
223. Iurescia, S., Fioretti, D., Mangialasche, F., and Rinaldi, M., The pathological cross talk between apolipoprotein E and amyloid-beta peptide in Alzheimer's disease: emerging gene-based therapeutic approaches. J Alzheimer's Dis 2010; 21(1): 35-48.
224. Mulder, S.D., Veerhuis, R., Blankenstein, M.A., and Nielsen, H.M., The effect of amyloid associated proteins on the expression of genes involved in amyloidbeta clearance by adult human astrocytes. Exp Neurol 2012; 233(1): 373-9.
225. Messier, C., Diabetes, Alzheimer's disease and apolipoprotein genotype. Exp Gerontol 2003; 38(9): 941-6.
226. Yip, A.G., McKee, A.C., Green, R.C., Wells, J., Young, H., Cupples, L.A., and Farrer, L.A., APOE, vascular pathology, and the AD brain. Neurology 2005; 65(2): 259-65.
227. Schrijvers, E.M., Witteman, J.C., Sijbrands, E.J., Hofman, A., Koudstaal, P.J., and Breteler, M.M., Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology 2010; 75(22): 1982-7.
228. VanFossen, B.T.,Watson, G.S., Baker, L.D., Rhoads, K.W., Cholerton, B.A., Reger, M.A., Plymate, S.R., Schellenberg, G., and Craft, S., Statin users without an APOE-epsilon4 allele have increased insulin resistance. J Alzheimer's Dis 2010; 19(4): 1149-53.
229. Ho, A. and Shen, J., Presenilins in synaptic function and disease. Trends Mol Med 2011; 17(11): 617-24.
230. Maesako, M., Uemura, K., Kuzuya, A., Sasaki, K., Asada, M., Watanabe, K., Ando, K., Kubota, M., Kihara, T., and Kinoshita, A., Presenilin regulates insulin signaling via a gamma-secretase-independent mechanism. J Biol Chem 2011; 286(28): 25309-16.
231. Maesako, M., Uemura, K., Kuzuya, A., Sasaki, K., Asada, M., Watanabe, K., Ando, K., Kubota, M., Akiyama, H., Takahashi, R., Kihara, T., Shimohama, S., and Kinoshita, A., Gain of function by phosphorylation in Presenilin 1-mediated regulation of insulin signaling. J Neurochem 2012; 121(6): 964-73.
232. Rosenberg, P.B., Clinical aspects of inflammation in Alzheimer's disease. Int Rev Psychiatry 2005; 17(6): 503-14.
233. Sastre, M., Klockgether, T., and Heneka, M.T., Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci 2006; 24(2-3): 167-76.
234. Summers, S.A., Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 2006; 45(1): 42-72.
235. Katsel, P., Li, C., and Haroutunian, V., Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochemical research 2007; 32(4-5): 845-56.
236. Summers, S.A., Sphingolipids and insulin resistance: the five Ws. Curr Opin Lipidol 2010; 21(2): 128-35.
237. Han, M.S., Park, S.Y., Shinzawa, K., Kim, S., Chung, K.W., Lee, J.H., Kwon, C.H., Lee, K.W., Park, C.K., Chung,W.J., Hwang, J.S., Yan, J.J., Song, D.K., Tsujimoto, Y., and Lee, M.S., Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes. J Lipid Res 2008; 49(1): 84-97.
238. Holland, W.L., Knotts, T.A., Chavez, J.A., Wang, L.P., Hoehn, K.L., and Summers, S.A., Lipid mediators of insulin resistance. Nutr Rev 2007; 65(6 Pt 2): S39-46.
239. Lipina, C. and Hundal, H.S., Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance. Diabetologia 2011; 54(7): 1596-607.
240. DeFronzo, R.A., Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010; 53(7): 1270-87.
241. Eckardt, K., Taube, A., and Eckel, J., Obesityassociated insulin resistance in skeletal muscle: role of lipid accumulation and physical inactivity. Rev Endocr Metab Disord 2011; 12(3): 163-72.
242. Consitt, L.A., Bell, J.A., and Houmard, J.A., Intramuscular lipid metabolism, insulin action, and obesity. IUBMB Life 2009; 61(1): 47-55.
243. Reynolds, C.P., Maurer, B.J., and Kolesnick, R.N., Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 2004; 206(2): 169-80.
244. Sonnino, S. and Prinetti, A., Lipids and membrane lateral organization. Front Physiol 2010; 1: 153.
245. Corre, I., Niaudet, C., and Paris, F., Plasma membrane signaling induced by ionizing radiation. Mutat Res 2010; 704(1-3): 61-7.
246. Hajduch, E., Balendran, A., Batty, I.H., Litherland, G.J., Blair, A.S., Downes, C.P., and Hundal, H.S., Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells. Diabetologia 2001; 44(2): 173-83.
247. Lingwood, D. and Simons, K., Lipid rafts as a membrane-organizing principle. Science 2010; 327(5961): 46-50.
248. Delarue, J. and Magnan, C., Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care 2007; 10(2): 142-8.
249. Liu, B., Obeid, L.M., and Hannun, Y.A., Sphingomyelinases in cell regulation. Semin Cell Dev Biol 1997; 8(3): 311-22.
250. Cong, W.N., Tao, R.Y., Tian, J.Y., Liu, G.T., and Ye, F., The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sci 2008; 82(19-20): 983-90.
251. Kolak, M., Westerbacka, J., Velagapudi, V.R., Wagsater, D., Yetukuri, L., Makkonen, J., Rissanen, A., Hakkinen, A.M., Lindell, M., Bergholm, R., Hamsten, A., Eriksson, P., Fisher, R.M., Oresic, M., and Yki-Jarvinen, H., Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007; 56(8): 1960-8.
252. Arboleda, G., Huang, T.J., Waters, C., Verkhratsky, A., Fernyhough, P., and Gibson, R.M., Insulinlike growth factor-1-dependent maintenance of neuronal metabolism through the phosphatidylinositol 3-kinase-Akt pathway is inhibited by C2-ceramide in CAD cells. Eur J Neurosci 2007; 25(10): 3030-8.
253. Chavez, J.A., Holland, W.L., Bar, J., Sandhoff, K., and Summers, S.A., Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling. J Biol Chem 2005; 280(20): 20148-53.
254. Chalfant, C.E., Kishikawa, K., Mumby, M.C., Kamibayashi, C., Bielawska, A., and Hannun, Y.A., Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J Biol Chem 1999; 274(29): 20313-7.
255. Bourbon, N.A., Sandirasegarane, L., and Kester, M., Ceramide-induced inhibition of Akt is mediated through protein kinase Czeta: implications for growth arrest. J Biol Chem 2002; 277(5): 3286-92.
256. Nogueira, T.C., Anhe, G.F., Carvalho, C.R., Curi, R., Bordin, S., and Carpinelli, A.R., Involvement of phosphatidylinositol-3 kinase/ AKT/PKCzeta/ lambda pathway in the effect of palmitate on glucoseinduced insulin secretion. Pancreas 2008; 37(3): 309-15.
257. Bryan, L., Kordula, T., Spiegel, S., and Milstien, S., Regulation and functions of sphingosine kinases in the brain. Biochim Biophys Acta 2008; 1781(9): 459-66.
258. Van Brocklyn, J.R., Sphingolipid signaling pathways as potential therapeutic targets in gliomas. Mini Rev Med Chem 2007; 7(10): 984-90.
259. Arboleda, G., Cardenas, Y., Rodriguez, Y., Morales, L.C., Matheus, L., and Arboleda, H., Differential regulation of AKT, MAPK and GSK3beta during C2-ceramide-induced neuronal death. Neurotoxicology 2010; 31(6): 687-93.
260. Stoica, B.A., Movsesyan, V.A., Lea, P.M.t., and Faden, A.I., Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3beta, and induction of the mitochondrial-dependent intrinsic caspase pathway. Mol Cell Neurosci 2003; 22(3): 365-82.
261. Hajduch, E., Turban, S., Le Liepvre, X., Le Lay, S., Lipina, C., Dimopoulos, N., Dugail, I., and Hundal, H.S., Targeting of PKCzeta and PKB to caveolinenriched microdomains represents a crucial step underpinning the disruption in PKB-directed signalling by ceramide. Biochem J 2008; 410(2): 369-79.
262. Longato, L., Ripp, K., Setshedi, M., Dostalek, M., Akhlaghi, F., Branda, M., Wands, J.R., and de la Monte, S.M., Insulin resistance, ceramide accumulation, and endoplasmic reticulum stress in human chronic alcohol-related liver disease. Oxid Med Cell Longev 2012; 2012: 479348.
263. Ramirez, T., Longato, L., Tong, M., Dostalek, M., Akhalghi, F., Wands, J.R., and de la Monte, S.M., Insulin resistance, ceramide accumulation, and endoplasmic reticulum stress in experimental chronic alcohol-induced steatohepatitis J Gastroenterol Hepatol 2012.
264. Meikle, P.J. and Christopher, M.J., Lipidomics is providing new insight into the metabolic syndrome and its sequelae. Current opinion in lipidology 2011; 22(3): 210-5.
265. de la Monte, S.M., Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Current Alzheimer research 2012; 9: 35-66.
266. Han, X., Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease. Biochimica et biophysica acta 2010; 1801(8): 774-83.
267. Mielke, M.M., Haughey, N.J., Ratnam Bandaru,V.V., Schech, S., Carrick, R., Carlson, M.C., Mori, S., Miller, M.I., Ceritoglu, C., Brown, T., Albert, M., and Lyketsos, C.G., Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimer's & dementia: the journal of the Alzheimer's Association 2010; 6(5): 378-85.
268. Mielke, M.M., Haughey, N.J., Bandaru, V.V., Weinberg, D.D., Darby, E., Zaidi, N., Pavlik, V., Doody, R.S., and Lyketsos, C.G., Plasma Sphingomyelins are Associated with Cognitive Progression in Alzheimer's Disease. Journal of Alzheimer's disease: JAD 2011; 27(2): 259-69.
269. Landreth, G., PPARgamma agonists as newtherapeutic agents for the treatment of Alzheimer's disease. Exp Neurol 2006; 199(2): 245-8.
270. Longato, L., Tong, M.,Wands, J.R., and de la Monte, S.M., High fat diet induced hepatic steatosis and insulin resistance: Role of dysregulated ceramide metabolism. Hepatol Res 2012; 42(4): 412-27.
271. Haughey, N.J., Steiner, J., Nath, A., McArthur, J.C., Sacktor, N., Pardo, C., and Bandaru, V.V., Converging roles for sphingolipids and cell stress in the progression of neuro-AIDS. Front Biosci 2008; 13: 5120-30.